Journal of Affective Disorders
January 15, 2016
Megha M Vasavada, Amber M Leaver, Randall Espinoza et al.
58 citations
Ketamine elicits an acute antidepressant effect in patients with major depressive disorder (MDD). Here, we used diffusion imaging to explore whether regional differences in white matter microstructure prior to treatment may predict clinical response 24h following ketamine infusion in 10 MDD patients. FSL's Tract-Based Spatial Statistics (TBSS) established voxel-level differences in fractional...
BMC Medical Ethics
January 14, 2016
Melvyn W B Zhang, Keith M. Harris, Roger Ho
69 citations
BACKGROUND: Depressive disorders are a common form of psychiatric illness and cause significant disability. Regulation authorities, the medical profession and the public require high safety standards for antidepressants to protect vulnerable psychiatric patients. Ketamine is a dissociative anaesthetic and a derivative of a hallucinogen (phencyclidine). Its abuse is a major worldwide public...
The World Journal of Biological Psychiatry
January 11, 2016
Matthew N. Cooper, Joshua D. Rosenblat, Danielle S. Cha et al.
40 citations
Objectives Replicated evidence has demonstrated that ketamine exerts rapid-acting and potent antidepressant effects. Notwithstanding, its promise to mitigate depressive symptoms and suicidality in antidepressant-resistant populations, several limitations and safety concerns accompany ketamine including, but not limited to, the potential for abuse and psychotomimetic/dissociative experiences....
2016
Michael A. Cerullo, A. Stryker
In severe depression thoughts of suicide can develop over weeks or months. Traditional pharmacologic or psychotherapeutic treatments take several weeks before they begin to improve symptoms. This gradual improvement is consistent with our everyday experience of the self. However, a new treatment, ketamine, can alter depressive symptoms within hours or even minutes. Ketamine can stop suicidal...
The Brown University Psychopharmacology Update
2016
A review and meta‐analysis of the effects of N‐methyl‐D‐aspartate (NMDA) receptor antagonists in treating major depression has confirmed that ketamine is the only such drug to date that has demonstrated antidepressant efficacy across multiple trials. Authors of the review stated, however, that the findings regarding ketamine should be viewed with caution because the beneficial effects are not...
PeerJ
2016
Jing J Wong, Owen O'Daly, Mitul A. Mehta et al.
Background. Ketamine has been reported to have efficacy as an antidepressant in several studies of treatment-resistant depression. In this study, we investigate whether an acute administration of ketamine leads to reductions in the functional connectivity of subgenual anterior cingulate cortex (sgACC) with other brain regions. Methods. Thirteen right-handed healthy male subjects underwent a 15...
Case Reports in Neurology
2016
Scott J Sherman, Miguel Estevez, Ari B Magill et al.
Ketamine is an FDA-approved drug with a known safety profile. Low-dose subanesthetic intravenous ketamine infusion treatment has led to long-term reduction of treatment-resistant depression and of chronic pain states. We report on low-dose subanesthetic intravenous ketamine infusion treatment in Parkinson's disease (PD) patients by 5 case studies and show a long-lasting therapeutic benefit to...
Biological Psychiatry
November 4, 2015
Jaskaran Singh, Maggie Fedgchin, Ella Daly et al.
466 citations
BACKGROUND: The purpose of this study was to assess the efficacy and safety and to explore the dose response of esketamine intravenous (IV) infusion in patients with treatment-resistant depression (TRD). METHODS: This multicenter, randomized, placebo-controlled trial was conducted in 30 patients with TRD. Patients were randomly assigned 1:1:1 to receive an IV infusion of .20 mg/kg or .40 mg/kg...
Journal of Psychiatric Practice
November 1, 2015
Ajay K. Parsaik, Balwinder Singh, Darrow Khosh-Chashm et al.
42 citations
Retracted
To consolidate the evidence from the literature to evaluate the role of ketamine in the treatment of bipolar depression. Major databases, including MEDLINE, EMBASE, Cochrane, and Scopus, were searched through October 2014, for studies reporting the role of ketamine in the treatment of bipolar depression. Only randomized controlled trials were included in the meta-analysis. We calculated...
Turkish journal of anaesthesiology and reanimation
October 2015
Özlem Özkan Kuşçu, Feride Karacaer, Ebru Biricik et al.
We aimed to evaluate the effect of anaesthesia with thiopental (4 mg kg(-1)), ketamine (1 mg kg(-1)) and ketamine-thiopental (1 mg kg(-1) and 4 mg kg(-1), respectively) combination during electroconvulsive therapy (ECT) on the Hamilton Depression Rating Scale (HDRS) and Hamilton Anxiety Rating Scale (HAM-A) and haemodynamic variables in patients with resistant major depression. Patients with...